Please login to the form below

Lexicon Pharmaceuticals

This page shows the latest Lexicon Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Sanofi exits Zynquista alliance with Lexicon

Will pay $260m to end collaboration. Following rejection from the FDA earlier this year, Sanofi has agreed to pay Lexicon Pharmaceuticals $260m to end the alliance formed to develop and ... for demonstrating cardiovascular and renal benefits,” said

Latest news

Ipsen searches for new CEO after splitting top roles

Ipsen licenses the drug from Lexicon Pharmaceuticals and has rights outside the US and Japan.
Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin. Sanofi and Lexicon Pharmaceuticals have agreed to collaborate in the development and commercialisation of sotagliflozin, an investigational new drug for diabetes. ... Pascale Witz, executive VP at
Lexicon announces IBS trial results

Lexicon Pharmaceuticals’ TPH inhibitor LX1031 has been shown in a phase II trial to be well tolerated and provide clinical benefit to patients with irritable bowel syndrome. ... The biopharmaceutical company Lexicon Pharmaceuticals has announced the
Lexicon reveals two agreements to fund long-term drug development

Lexicon Pharmaceuticals has entered into a major financing agreement with Invus Group to help fund the company's transition into an integrated biopharmaceutical company. ... US biopharmaceutical company Lexicon Pharmaceuticals has entered into a major

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch November 2016

Licensor Acquired/ Licensee Acquirer. Product/ Technology. Deal Type. Headline ($m). Selexys Pharmaceuticals/ Novartis. ... Strategic alliance, options. 122.7 per. BMS/ Lexicon Pharmaceuticals. BMS-986176 for neutopathic pain (pc) plus other small
Deal Watch November 2015

Staying with diabetes, so strategically important, Sanofi put in place a collaboration with Lexicon Pharmaceuticals for sotagliflozin (LX4211), an oral treatment for type 1 and type 2 diabetes. ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration,
Deal Watch table for October 2014

For multivalent MVA-BN Filovirus vaccine. 187. Lexicon Pharmaceuticals/Ipsen. Licence [B]. Telotristat etiprate in P3 for carcinoid syndrome.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Linda Law joins Advicenne as US VP, clinical development and med affairs

Law’s career has seen her serve in various positions for pharmaceutical companies including Procter &Gamble, Lexicon Pharmaceuticals and she has consulted on evaluation and development projects with Takeda, Confluence and ... Forest Pharmaceuticals.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...